Hospital.Help

New York An increase in vaso-occlusive crises and deaths in 2 postmarketing studies has led the manufacturer Pfizer to withdraw the drug Oxbryta (active ingredient voxelotor) for the treatment of sickle cell disease from the market worldwide. The European Medicines Agency (EMA) expressed concerns in a safety review and recommended suspending the approval. Oxbryta was in the US in November 2019 and in the EU in February 2022…